| | | | | |

New Mesothelioma Trial to Test Tri-Modal Approach

ByAlex Strauss

new mesothelioma trialEnrollment is open for a new mesothelioma trial run by Memorial Sloan Kettering Cancer Center to test a three-prong approach to treatment. 

Pleural mesothelioma is a lung-related cancer caused by asbestos. It is notoriously difficult to treat and highly aggressive. 

The new mesothelioma trial aims to recruit 150 pleural mesothelioma patients. Patients will receive lung-sparing surgery and chemotherapy. Some will also receive intensity modulated radiation therapy (IMRT). 

Researchers will test which group does better – those who only have surgery and chemotherapy or those who also have targeted radiation therapy. They plan to measure not only survival but also complications, quality of life, and how long it takes for the cancer to come back. 

Tri-Modal Treatment to Fight Mesothelioma

The new mesothelioma trial will attempt to answer some questions about the disease and its treatment. Doctors have known for a long time that pleural mesothelioma rarely responds to one kind of therapy. Mesothelioma patients who have the best survival are those who have at least two kinds of treatments. 

But not all patients are candidates for a multi-modality approach. Some mesothelioma patients are too sick for anything but chemotherapy. Mesothelioma chemotherapy can help slow the growth of tumors but it is not a cure. 

Patients who are well enough may have surgery. One type of mesothelioma surgery (EPP) involves removing one of the lungs. The other type (P/D) leaves both lungs intact but removes other at-risk tissues. 

The new mesothelioma trial focuses on P/D. Some studies show that survival is better with this more conservative type of surgery. Both types of surgery achieve the best outcomes when they are done at a higher-volume medical center. 

Who is Eligible for the New Mesothelioma Trial? 

The new mesothelioma trial is looking for newly diagnosed mesothelioma patients. Patients must be candidates for surgery and chemotherapy. Most patients will have chemotherapy after surgery (adjuvant). Some may have chemotherapy before surgery (neoadjuvant) in an effort to shrink the tumor before removal.

Within 8 weeks of their last treatment, patients will be randomly assigned to one of two groups. One group will get radiation with IMPRINT. IMPRINT stands for intensity modulated pleural radiation therapy. It is a type of highly targeted radiotherapy developed at Memorial Sloan Kettering. Targeted radiotherapy is less likely to impact healthy tissue and trigger side effects. 

The second group in the new mesothelioma trial will have no further treatment. 

“The primary endpoint of the study is overall survival,” writes radiation oncologist Andreas Rimner, MD.  “Secondary endpoints include local failure-free, distant-metastases free and progression-free survival, treatment-related toxicities, and change in quality-of-life.”

Sixteen hospitals have been approved to offer the new mesothelioma trial. Another 46 sites are pending approval. Researchers hope to have some answers by July of 2025. 

CLICK HERE to learn more about this clinical trial including eligibility criteria. 

Sources:

Rimner, A, et al, “A Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) (NRG LU-006)”, November 1, 2021, International Journal of Radiation Oncology, Biology, Physics, Volume 111, Issue 3, Supplement, https://www.redjournal.org/article/S0360-3016(21)02168-4/fulltext#relatedArticles

“Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma”, ClinicalTrials.gov Identifier: NCT04158141, https://clinicaltrials.gov/ct2/show/NCT04158141?term=IMPRINT&recrs=ab&cond=pleural+mesothelioma&cntry=US&draw=2&rank=2

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    ByAlex Strauss

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    ByAlex Strauss

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…